Comparative Pharmacology
Head-to-head clinical analysis: ESOMEPRAZOLE SODIUM versus NEXIUM 24HR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESOMEPRAZOLE SODIUM versus NEXIUM 24HR.
ESOMEPRAZOLE SODIUM vs NEXIUM 24HR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor that irreversibly inhibits the H+/K+-ATPase enzyme system (proton pump) in gastric parietal cells, suppressing gastric acid secretion.
Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells. It is a weak base that accumulates in the acidic environment of the parietal cell canaliculus, where it is protonated and converted to the active achiral sulfenamide form, which forms a covalent disulfide bond with cysteine residues of the H+/K+ ATPase, irreversibly inhibiting the pump.
20-40 mg IV once daily for up to 10 days; oral: 20-40 mg once daily for 4-8 weeks for erosive esophagitis, 20 mg once daily for gastroesophageal reflux disease.
20 mg orally once daily for 14 days for frequent heartburn; for gastroesophageal reflux disease (GERD), 20 mg orally once daily for 4-8 weeks; for erosive esophagitis, 20-40 mg orally once daily for 4-8 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 1–1.5 hours in healthy individuals; clinical context: longer half-life (~2–3 hours) in slow CYP2C19 metabolizers, but acid suppression lasts longer due to irreversible binding to H+/K+-ATPase.
The terminal elimination half-life is approximately 1-2 hours in healthy individuals. However, the pharmacodynamic effect (acid suppression) lasts longer due to accumulation in the parietal cell canaliculus and irreversible binding to the proton pump. In poor CYP2C19 metabolizers, half-life may extend to 3-4 hours.
Primarily hepatic metabolism (~80%) via CYP2C19 and CYP3A4; renal excretion of inactive metabolites accounts for ~80% of an oral dose, with ~20% excreted in feces via bile.
Approximately 77% of a single oral dose is excreted in urine as metabolites (primarily hydroxy- and desmethyl-omeprazole) and glucuronide conjugates, with less than 1% as unchanged drug. About 19% is eliminated in feces via biliary excretion. Renal clearance accounts for the majority of elimination.
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor